Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer.
暂无分享,去创建一个
Kazuyuki Aihara | Yoshito Hirata | Nicholas Bruchovsky | Mario di Bernardo | K. Aihara | M. di Bernardo | Yoshito Hirata | N. Bruchovsky
[1] P. Carroll,et al. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. , 2001, Urology.
[2] Richard P. Hill,et al. The Basic Science of Oncology , 1989 .
[3] Gouhei Tanaka,et al. A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer , 2008, J. Nonlinear Sci..
[4] Gouhei Tanaka,et al. Bifurcation analysis on a hybrid systems model of intermittent hormonal therapy for prostate cancer , 2008 .
[5] M. Peyromaure,et al. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience. , 2005, Urology.
[6] Gouhei Tanaka,et al. Mathematical modelling of prostate cancer growth and its application to hormone therapy , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.
[7] J. Cuzick,et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta‐analysis of 1446 patients , 2007, BJU international.
[8] Nicholas Bruchovsky,et al. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer , 2006, Cancer.
[9] N. Mottet,et al. The role of intermittent androgen deprivation in prostate cancer , 2007, BJU international.
[10] Kazuyuki Aihara,et al. Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. , 2010, Journal of theoretical biology.
[11] A. De la taille,et al. Intermittent androgen suppression in patients with prostate cancer , 2003, BJU international.
[12] Kazuyuki Aihara,et al. Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.
[13] L. Eapen,et al. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome. , 2007, International journal of radiation oncology, biology, physics.
[14] R. Jennrich,et al. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. , 2007, Urology.
[15] M. Gleave,et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. , 1995, Urology.
[16] Kazuyuki Aihara,et al. A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer. , 2008, Mathematical biosciences.
[17] N. Sato,et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. , 2004, Urology.
[18] S. Goldenberg,et al. Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.